z-logo
Premium
Distinctive lupus panniculitis of scalp with linear alopecia along Blaschko's lines: a review of the literature
Author(s) -
Lueangarun Suparuj,
Subpayasarn Urairack,
Tempark Therdpong
Publication year - 2019
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.14155
Subject(s) - medicine , panniculitis , scalp , hydroxychloroquine , systemic lupus erythematosus , dermatology , lupus erythematosus , prednisolone , discoid lupus erythematosus , pathology , disease , immunology , covid-19 , infectious disease (medical specialty) , antibody
Abstract Lupus panniculitis of the scalp ( LPS ) is a rare and distinctive clinical feature of lupus erythematosus panniculitis ( LEP ) with linear alopecia along Blaschko's lines. In this study, we investigated clinical features and treatments of LPS by literature review of articles in the English language from PubMed and SCOPUS databases up to April 2018. The following key words, “lupus panniculitis, “lupus erythematosus panniculitis”, “lupus profundus”, “head”, and “scalp”, were used. Twenty cases of LPS were identified (mean age = 26.4 [10–53] years, female: male ratio = 1:1, mean disease duration = 86.89 [8–336] weeks). The most commonly affected areas of scalp included parietal (70%), frontal (45%), temporal (40%), occipital (30%), and vertex (10%), along 70% of Blaschko's lines with morphologic lesions linear, annular, arch‐shaped, and ulcer. Besides, ANA (60%) was in particular noted. Hydroxychloroquine, oral prednisolone, intralesional corticosteroid, and methotrexate were the most common treatments, with complete response after an average period of 8.08 (2–12) weeks. Systemic lupus erythematosus ( SLE ) was developed in four cases (20%) during follow‐up, with high recurrence of 35%. We reported distinctive and rare cases of LPS .The continuing follow‐up was highly recommended to avoid probable recurrence and SLE development.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here